Nature Made® Named Top Vitamin Brand in U.S. News & World Report's 2025 Survey with Eight #1 Rankings
In partnership with global market research firm The Harris Poll, U.S. News surveyed 357 pharmacists and 134 dermatologists practicing in the United States regarding 133 categories.
The results ranked Nature Made as the #1 for:
Best Vitamin Brands
Best Anti-Stress Supplement
Best Ashwagandha Supplements
Best Potassium Supplements
Best Turmeric Supplements
Best Vitamin B12 Supplements
Best Prenatal Vitamins
Best Vitamin D Supplements
"We're honored that Nature Made has once again been recognized by healthcare professionals as a trusted leader across so many essential categories," said Pharmavite CEO Jeff Boutelle. "From foundational vitamins like B12 and potassium to targeted solutions for stress, this recognition reflects our commitment to quality, science, and supporting consumers' evolving needs on every step of their health and wellness journeys."
To determine the rankings, panelists selected their top three recommended brands within each category assigned to them. The brands that were highly ranked most often were then named category winners. U.S. News awarded the designations of Best OTC Medicine & Health Products only to brands that met the outlet's statistical assessment of performance on the survey.
"U.S. News' Best OTC Medicine & Health Products rankings offer consumers a reliable guide in a crowded marketplace. By surveying hundreds of practicing pharmacists and dermatologists, we provide data-driven insights to help individuals and families confidently select the highest-quality over-the-counter options for their health needs," said Sumita Singh, general manager of Health at U.S. News & World Report.
Full survey results and details can be found online via Best OTC Medicine & Health Products, courtesy of U.S. News & World Report. Those looking to choose a health product should consult with a medical professional as part of their decision-making process.
For more information on U.S. News & World Report's Best OTC Medicine & Health Products, visit U.S. News & World Report on Facebook, Instagram, TikTok and X and explore using the hashtag #BestOTCProducts.
*Based on a survey of pharmacists who recommend branded vitamins and supplements
About Pharmavite LLC
Pharmavite is a pioneer in the health and wellness industry, earning the trust of consumers, healthcare professionals and retailers by developing innovative vitamin and supplement ingredients backed by science that adhere to strict manufacturing practices. Through its Nature Made®, Bonafide®, Nature Made® Wellblends, Equelle®, MegaFood®, and Uqora® brands, Pharmavite is dedicated to helping people live healthier, more vital lives. Based in California, Pharmavite is a subsidiary of Otsuka Pharmaceutical Co., Ltd. Visit www.pharmavite.com and follow us on LinkedIn for the latest news and information about Pharmavite and its brands.
About Nature Made Vitamins
Nature Made® is a leading national vitamin and supplement broadline brand, with over 50 years of expertise in delivering high quality products with ingredients that are backed by science. Ranked as the #1 Pharmacist Recommended vitamin and supplement brand*, Nature Made was first to earn the United States Pharmacopeia's (USP) Verified Dietary Supplement mark for many of its products – independent verification that products meet stringent quality criteria for purity and potency. Visit www.NatureMade.com for the latest news and offerings and follow us on Facebook (@naturemade), Instagram (@naturemadevitamins), and TikTok (@naturemadevitamins).
*Based on a survey of pharmacists who recommend branded vitamins and supplements
About U.S. News & World Report
U.S. News & World Report is the global leader for journalism that empowers consumers, citizens, business leaders and policy officials to make confident decisions in all aspects of their lives and communities. A multifaceted media company, U.S. News provides unbiased rankings, independent reporting and analysis, and consumer advice to millions of people on USNews.com each month. A pillar in Washington for more than 90 years, U.S. News is the trusted home for in-depth and exclusive insights on education, health, politics, the economy, personal finance, travel, automobiles, real estate, careers and consumer products and services.
About The Harris Poll
The Harris Poll is a global public opinion, analytics, and market research consultancy that strives to reveal society's authentic values to inspire leaders to create a better tomorrow. With a global research reach of more than ninety countries, Harris offers advisory services across sectors to world leaders, CEOs, and business decision-makers with state-of-the-art analytics, real-time software services, and practitioners in marketing, reputation, customer experience, trends, futures, and thought leadership/research-for-public release, The Harris Poll translates shifting social sentiment into a competitive marketplace advantage. Harris is a Stagwell (NASDAQ: STGW) company. www.theharrispoll.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250708987880/en/
Contacts
Media Contact: Julia Chamberlin, jchamberlin@pharmavite.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in to access your portfolio
Gizmodo
4 minutes ago
- Gizmodo
Researchers Find Strange Link Between Marathon Running and Cancer
Some of the most physically fit people in the world may have a unique health risk. New research uncovers a possible link between marathon running and colorectal cancer. Oncologists at the Inova Schar Cancer Institute in Virginia conducted the study, which examined the colons of relatively young people who had run several long-distance races. They found these runners had a much higher rate of having potentially dangerous adenomas (a type of polyp) than would be expected for their age. Though the findings are preliminary and require more confirmation, they may point to a real connection between colorectal cancer and extreme physical activity. 'It tells us there's a signal here,' David Lieberman, a gastroenterologist and professor emeritus at Oregon Health and Science University not affiliated with the study, told the New York Times Tuesday. 'We wouldn't have expected these rates of high-risk adenomas, which are cancer precursor lesions, in an age group like this.' Lead researcher Timothy Cannon was inspired to perform the study after he treated three young patients with colorectal cancer, all of whom had run ultramarathons (defined as any race longer than 26.2 miles). Not only were his patients fit, but they were also much younger than the typical case, the oldest being 40. In 2022, Cannon and his colleagues began recruiting endurance athletes for their prospective study. The volunteers had all run at least two ultramarathons or five regular marathons; they also had no family history of colorectal cancer or other apparent risk factors. All told, 100 athletes between the ages of 35 and 50 took part and were given colonoscopies. People Who Are More Flexible Tend to Live Longer, Study Finds The researchers went looking for advanced adenomas in the colons of their volunteers, relatively large or otherwise unusual polyps. Though these growths are themselves benign, they have a higher risk of turning cancerous than other polyps. Then they compared the rate of finding these polyps in their athletes to historical trends. About 1.2% of people in their 40s at average risk for colorectal cancer would be expected to have advanced adenomas, according to the researchers. By sharp contrast, 15% of the runners they studied had them, while nearly half had polyps in general. 'Consideration of refined screening strategies for this population is warranted,' the researchers wrote in their study. The team presented its results earlier this year at the annual conference of the American Society of Clinical Oncology. That means this study hasn't yet undergone the formal peer-review process. The authors are also quick to note their work isn't definitive proof that endurance running can cause colorectal cancer. Assuming this link is causative, there remains the burning question of why. As even weekend 5k joggers will know, running can occasionally trigger bouts of gastrointestinal distress (the namesake runner's diarrhea). These injuries are sometimes caused by temporarily restricted blood flow to the intestines that damages nearby cells. It's possible, the researchers speculate, that extreme runners who regularly experience this blood flow loss can develop the sort of chronic inflammation that makes cancer more likely to emerge. Being a Couch Potato Is Bad for Your Memory, Study Warns At this point, though, that's only one hypothesis for what may be happening here. The researchers say future studies should try to confirm their findings as well as untangle the causes and risk factors that could explain this potential higher risk. All that said, this research shouldn't scare anyone away from running or any other form of cardio. The many health benefits of regular physical activity—which importantly include a lower risk of at least eight different types of cancer—still far outweigh the risks for the average person.
Wall Street Journal
7 minutes ago
- Wall Street Journal
The Necessity of ObamaCare
In 'The Phantom Patients of ObamaCare' (Aug. 18), you write that because millions of Americans 'don't use' their subsidized insurance, they therefore 'don't need' it. Yet as we teach our students every year, this misunderstands the purpose of insurance. Not filing a claim doesn't mean you didn't need insurance. We've never had to use our oxygen masks during decades of flying, but that hardly means they're not essential. Prof. Amy Finkelstein
